tert-Butyl 3,3-dimethyl-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxylate

Catalog No. :
ACQDPB977
CAS No. :
1956383-42-8
Molecular Formula :
C19H27NO3
Molecular Weight :
317.43

IUPAC Name:tert-butyl 3,3-dimethyl-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxylate

tert-Butyl 3,3-dimethyl-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$424.00Login to see priceInquiryInquiry
1g97%$1060.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3,3-dimethyl-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxylate
IUPAC Nametert-butyl 3,3-dimethyl-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxylate
Molecular FormulaC19H27NO3
Molecular Weight317.43
SMILESO=C(N1CCC2(CC1)OC(C)(C)C3=C2C=CC=C3)OC(C)(C)C
InChI KeyQYXIYJQFXUASNQ-UHFFFAOYSA-N
SynonymTert-butyl 3,3-dimethylspiro[2-benzofuran-1,4'-piperidine]-1'-carboxylate;Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxylic acid, 3,3-dimethyl-, 1,1-dimethylethyl ester;tert-butyl 3,3-dimethyl-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxylate
CAS No.1956383-42-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACQDPB977 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQDPB977 route product structure diagram
    ACQDPB9771956383-42-8
Inquiry

2. ACQDPB977 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQDPB977 route product structure diagram
    ACQDPB9771956383-42-8
Inquiry

Comments (0)